Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,501–2,600 of 3,116
Mironova, M., Ratziu, V., Rinella, M. E., Bansal, M. B., Noureddin, M., Alkhouri, N., Anstee, Q. M., Newsome, P. N., Schattenberg, J. M., Sanyal, A. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-340031
a systematic analysis for the Global Burden of Disease Study 2023
Hay, S. I., Ong, K. L., Santomauro, D. F., Bhoomadevi, A., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Park, J., Kim, J. H., Kim, Y. S., Lim, G., Song, H. J., Rhee, S. Y., Hwang, S., Cho, D. H., Kim, M. S., Kim, B., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71065
Visceral adiposity, aortic stiffness, and cardiovascular risk
Harada, T., & Borlaug, B. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf516
Samajdar, S. S., Joshi, S., SABOO, B., Mukherjee, S., & Misra, A. (2026) · Diabetology International · doi:10.1007/s13340-026-00910-9
Liu, K.-H., Chen, I., & Lin, W.-R. (2025) · Springer eBooks · doi:10.1007/978-981-95-2648-2_11
Yousafzai, O. K., Kanwal, K., Annie, F., & Rinehart, S. (2026) · medRxiv · doi:10.64898/2026.04.13.26350824
Мамедов, М. Н., Друк, И. В., & Akhundova, H. R. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6812
Vijayasimha, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02649-w
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · Nervenheilkunde · doi:10.1055/a-2939-1909
Yagi, K., Chujo, D., Usui, I., Liu, J., Nohara, A., Enkaku, A., Takikawa, A., Honoki, H., Fujisaka, S., Origasa, H., et al. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.103551 · Cited by 1
Peripheral artery disease: advances in medical therapy
Garagoli, F., Slipczuk, L. N., Shapiro, M. D., Bonaca, M. P., & Bhatt, D. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag516 · Cited by 3
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Capón, I. M., Sandino, J., Galindo, M., & Morales, E. (2026) · Drugs · doi:10.1007/s40265-026-02337-7 · Cited by 2
Chang, S., Tang, Y., Wang, M., Zhu, S., Tan, X., Fan, X., Lu, L., Duan, B., & Shen, L. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062121 · Cited by 2
Rethinking cardiometabolic therapy thresholds in individuals with obesity
Khanna, S., Nerlekar, N., & Bhat, A. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02160-w
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis
Armentaro, G., Severini, G., Pastura, C. A., Scarcelli, M. R., Cassano, V., & Sciacqua, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04438-3
Senapati, S. G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1891078 · Cited by 1
“In the SELECT study, it was found that semaglutide reduced the incidence of major cardiovascular events in patients with cardiovascular disease along with overweight or obesity, but no diabetes (40).”
GLP-1-Rezeptoragonisten bei Übergewicht
Weiler, S., & Egermann, U. (2026) · pharma-kritik · doi:10.37667/pk.2026.1450
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Parlati, A. L. M., Martini, L., Nardi, E., Carluccio, R., Parlati, L. E., Madaudo, C., & Filardi, P. P. (2026) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468261460202 · Cited by 3
Kim, S., Barthel, A., Smurzynski, M., & MacEwan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71033
Sinaga, N., & Sirait, L. (2026) · Health & Medical Sciences · doi:10.47134/phms.v3i3.631
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
ElNemer, W. G., Ghaith, A. K., Selim, O. A., Radwan, H., Zermeno, J.-R., & Fox, W. C. (2026) · Neurosurgical Review · doi:10.1007/s10143-026-04317-7
Semaglutid kan være aktuelt for mange
Lee-Ødegård, S., Valderhaug, T. G., Myhre, P. L., & Tonstad, S. (2024) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.24.0133
Monami, M., Bertoli, S., Ciudin, A., McGowan, B. M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70956 · Cited by 1
Abbas, R., & Sharma, V. (2026) · Health Marketing Quarterly · doi:10.1080/07359683.2026.2687299 · Cited by 2
Chashchin, M. G., Velichko, A. M., Glechyan, A. M., Emelyanov, A. V., Gorshkov, A. Y., & Drapkina, O. M. (2026) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2026-3246
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Brie, D. M., Mornoş, C., Tîrziu, A., Popescu, R., & Brie, A. D. (2026) · Pharmaceuticals · doi:10.3390/ph19091370
“Meta-analyses by Hu et al., using echocardiography and radionuclide angiography as endpoints, and the broader narrative synthesis by Chierchia et al. reach the same qualitative conclusion: improvements in left ventricular function were reported across these small, pre-modern-therapy studies [34,48].”
Obesity and female reproductive health in Asian population
Panyakhamlerd, K., Sophonsritsuk, A., Pantasri, T., Suwan, A., Panyawongudom, N., & Samakkarnthai, P. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100255 · Cited by 1
Metabolic Crosstalk in Heart Failure
Silvetti, S., Pagan, A., & Pieri, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-01024-7_22
Reappraising obesity management in the GLP-1 receptor agonist era
Christmas, T., Ahmed, A. R., & Tan, T. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00126-0
Liu, T., Ren, X., Li, Y., Wang, J., Chen, J., 林柔嘉, & Zhang, J. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2714331
“Recent outcome data have further extended its clinical relevance in obesity-related cardio-vascular risk reduction 13 . longer-term studies have also supported the durability of weight reduction with once-weekly semaglutide in adults with overweight or obesity 14 . its clinical success is closely…”
Bartošková, K., & Motovska, Z. J. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.018
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., Vasconcellos, M. D. O., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676 · Cited by 8
Supervía, M., de Murieta, E. S., Figueroa, J., Arroyo-Riaño, M. O., de Munain, M. L. L., de Miguel, C., Laxe, S., Marco, E., & Morata, A. B. (2026) · Rehabilitación · doi:10.1016/j.rh.2026.100968
Arena, R. A., Pronk, N. P., & Lavie, C. J. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102676
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
Beyond One-Size-Fits-All: Individually Tailored Dietary Interventions in Modern Obesity Care
Cozma-Petruț, A. P., Gherghel, M., Banc, R., Tișa, I. B., Stanciu, O., Coldea, T. E., Mudura, E., Miere, D., & Filip, L. A. (2026) · Nutrients · doi:10.3390/nu18162691 · Cited by 1
“…weight loss, emerging evidence suggests that these therapies provide beneficial effects across several obesity-associated comorbidities, including cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and certain types of cancer [147,153–156].”
Lee, S., & Baldus, S. E. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-02014-z
Zhu, C., & Liu, N. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08629-x · Cited by 1
“Their ability to promote sus - tained weight loss, along with improvements in cardio - vascular risk factors, has led to increased interest in their application beyond diabetes, particularly in the context of MBS [7].”
Clinical and economic aspects of semaglutide use in the treatment of obesity
Tibilova, A. L., Kozaeva, D. D., Aslakhanova, R. R., Tedety, V. Z., Tazurkaeva, M. Z., Gurtsieva, D. E., Kanteeva, E. E., Gabueva, M. S., Guatsaeva, V. I., Dzhigkaeva, A. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.369
Bozkurt, B. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102631
Cuculić, M. T., Sergo, D., Kavazović, I., Peršić, V., Wensveen, F. M., & Wensveen, T. T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922668
“…cardiovascular and renal outcome trials demonstrating bene fi ts in individuals without diabetes, such as the EMPEROR-preserved and SELECT trials (10, 11), these data support the notion that SGLT2 inhibitors and GLP-1 receptor agonists confer cardiovascular protection that is only partly…”
Selective amylin receptor agonism: promise beyond incretins
van Beek, A. P. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02214-7
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156026
“Direct mortality evidence is nonetheless accumulating: meta-analyses and large trial programmes report reductions in all-cause and cardiovascular mortality with GLP-1 RAs in populations with cardiovascular or renal disease [4,18].”
InfluentialBenefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans
Dall, T. M., Chen, F., Sapra, T., Ferguson, C., Hafida, S., Livingston, T., Moody, A., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0006 · Cited by 1
Retuerto, M., Fernández, I. G., Ramos, M. A., Fernández, I. G., Blanco, A. V., Sanz, A. M., Rivero-Lezcano, O. M., & Díez‐Álvarez, E. (2026) · RMD Open · doi:10.1136/rmdopen-2026-007122
Selecting Pharmacologic Interventions for MASH
Pan, J. J., Horwich, B., Chahine, M., Gutierrez, J. A., & Saab, S. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10003-x
“In nondiabetic patients with obesity (BMI ≥ 30 kg/m 2 ) and pre-existing cardiovascular disease, semaglutide 2.4 mg weekly was associated with an 18% relative risk reduction in MACE [24].”
InfluentialKlepacz, J., Swędrak, R., & Dobrakowska, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6638
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Patoulias, D., Karakasis, P., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2435426 · Cited by 1
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Hsieh, W. C., Henry, B. M., & Édes, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70907 · Cited by 1
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
Prakash, S., Coleman, J., & Steinfeldt, J. (2024) · medRxiv · doi:10.1101/2024.09.17.24313797
An Update of Oxidative Stress in Atherosclerosis with Emphasis on the LOX-1–NLRP3 Inflammasome Axis
Garg, K. G., Gautam, N., Agrawal, A., & Mehta, J. L. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01462-8
“In the SELECT trial, semaglutide 2.4 mg weekly reduced MACE by 20% in patients with obesity and established ASCVD without diabetes [ 108 – 111].”
InfluentialPrevenzione secondaria nel paziente affetto da coronaropatia
Sorbets, E. (2025) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(25)51186-5
Social Drivers of Health Advisory
Breathett, K. K., Khavjou, O., Maddox, K. E. J., Knapp, S. M., Dowd, W. N., Aguayo, L., Echols, M. R., Hammond, G., Hayman, L. L., Kershaw, K. N., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103101
Stereotypes and Discrimination Toward Weight Loss Injection Users
Sprengholz, P., & Klöckner, M. (2026) · Journal of Applied Social Psychology · doi:10.1111/jasp.70070
Cree, M. G., Dunsmoor-Su, R. F., Khoudary, S. R. E., Hurtado, M. D., Kapoor, E., Neal-Perry, G. S., & Santoro, N. F. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100321
“In the SELECT trial, which included patients with a BMI ≥ 27 and preexisting CVD without T2D, treatment with semaglutide 2.4 mg was associated with reduced incidence of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke [69].”
InfluentialOral Semaglutide in Adults with Overweight or Obesity
Wharton, S., do Vale, R. D., & Garvey, W. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2515109
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
How Somatic Mutations cause Aging without Causing AgingPreprint
Wolf, A. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6431458
Celebi, O., Gümüş, D., & Gümüş, Ö. (2026) · Healthcare · doi:10.3390/healthcare14152362
“SELECT further showed a 20% reduction in major cardiovascular events with semaglutide versus placebo in this population [10].”
ПЛЕЙОТРОПНЫЕ ЭФФЕКТЫ АГОНИСТОВ РЕЦЕПТОРОВ ГЛЮКАГОНОПОДОБНОГО ПЕПТИДА‑1
Юрьевич, Ц. В., Lazareva, I. A., Владимировна, Б. Н., Полякова, О. В., & Николаевна, У. С. (2026) · Современные проблемы науки и образования · doi:10.17513/spno.34690
Less water, not less fat: empagliflozin unloads myocardial volumes in obese patients
Tortigue, M., Paillard, M., & Mewton, N. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag110
Jain, R. (2026) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_94_25
Stafeev, I., Agareva, M. Y., Michurina, S. S., Tomilova, A., Shestakova, E. A., Voznesenskaya, А. А., Sineokaya, M. S., Alekseeva, N., Boldyreva, M. A., Ratner, E. I., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00033.2025
Diabetes Update 2024 – wertvolle neue Erkenntnisse
Scherbaum, W. A. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01205-w
Beyond Body Mass Index: Body Roundness Index, Inflammation, and Death
Lin, D. S., Chua, S., & Lee, J. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.048324
Exercise and glucagon-like peptide 1 receptor agonists in cardiovascular disease beyond weight loss
Jordan, A. J., & McDermott, M. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01560-6
Semaglutide as a potential tool in pre–lung transplant weight loss optimization
Ali, R., Keyt, H., Solis‐Herrera, C., & Escobar-Vasco, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag040
“…demonstrated that semaglutide reduced cardiovascular major adverse events such as nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death in patients with diabetes, and the SELECT trial thereafter suggested similar cardiovascular benefits in patients with obesity alone [7, 8].”
Clinical Impact of Semaglutide in Patients with Heart Failure and Preserved Ejection Fraction
Hida, Y., Imamura, T., & Kinugawa, K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124831
“Previous studies suggest that semaglutide reduces body weight https://doi.org/10.3390/jcm15124831 across a broad range of baseline body mass index [11,12,31].”
InfluentialCumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study
Turchin, A., Shubina, M., Morrison, F. J. R., Ahmad, N. N., Neff, L. M., & Kan, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344620
“In fact, several weight-loss interventions have already been shown to reduce the risk of range of adverse cardiovascular events [30,31].”
Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus
Henson, J. J., Davies, M. J., Greaves, C., Khunti, K., & Yates, T. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00003-3
The GLP ‐1–Mitochondria Axis in Metabolic Aging
Chang, R., Tsai, A. P., Wang, B., & Li, C. (2026) · Aging Cell · doi:10.1111/acel.70676 · Cited by 1
Medikamentöse Prävention der KHK: Welche Strategien stehen uns zur Verfügung?
Arnold, N., & Blankenberg, S. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2539-6112
World Kidney Day 2024: promoting equitable access to health care and optimal medication
Silvariño, R., Rico-Fontalvo, J. E., Villavicencio, V., Sánchez-Polo, V., & Rosa-Diez, G. J. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000034
Goryanin, I., Damms, B., & Goryanin, I. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70322 · Cited by 1
GLP-1-Rezeptor-Agonisten bei Bluthochdruck und Übergewicht
Babic, M., & van der Giet, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00887-7
Tian, Z., Willerding, J. M., Schmidt-Ott, K. M., Melk, A., & Schmidt, B. M. W. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104176
The expanding role of peptides in cardiovascular care
Romero, A. F. P., & Martinez, C. A. (2026) · Diabetes and Vascular Disease Research · doi:10.1177/14791641261476328
Unanticipated Effects of GLP ‐1 Receptor Agonists: A Net Positive
Gilden, A. H., & Heymsfield, S. B. (2026) · Obesity · doi:10.1002/oby.70288
“…use of semaglutide titrated to 2.4 mg led to an absolute reduction in risk of major cardio-vascular events (death, myocardial infarction, or stroke) of 1.5% (hazard ratio [HR]: 0.80), with an average weight loss of 9.4% in the medication treated group, versus 0.9% in the placebo treated group [3].”
InfluentialUpdates in pharmacotherapy of obesity
Ogunsakin, A. A., Olakunde, T. I., Fehintola, M. D., Malmberg, I. R., Olakunde, A., & Dokun, A. O. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.09.004 · Cited by 1
Maximizing Obesity Therapy: Strategic Use of Anti-obesity Pharmacotherapy
Bartfield, J. K., & Bonnecaze, A. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_70
Beyond BMI: why heart failure trials must quantify adiposity, not just obesity
Bayés‐Genís, A., & Schiattarella, G. G. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag046
Pollmann, D. L., Parry, J., Cravero, E., Benson, G. A., Sanchez, O. A., White, S., Stanberry, L. I., Wambach, C., & Miedema, M. D. (2025) · medRxiv · doi:10.1101/2025.08.01.25332846
Maranta, F., Buffoli, F., Giudici, V., et al. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200272
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Patient characteristics and early experiences with anti-obesity medications: the CAMP study
Tewksbury, C. M., Soliva, E. A., Scheffey, K., Kwong, P. L., & Glanz, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1931188
“In addition to weight loss, these medications have been associated with improvements in cardiometabolic risk factors and obesity-related comorbidities (10, 11).”
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD
Razzak, I. A., Razzak, I. A., Noureddin, M., & Trivedi, H. D. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002210 · Cited by 1
Mechanism and Context: Making Sense of Adverse Events With GLP-1-based Therapy
Hagelqvist, P. G., Vilsbøll, T., & Andreasen, C. R. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf232
“Moreover, large trials such as SELECT (semaglutide in obesity without diabetes; n = 17 604) [7] and across the SURPASS program (tirzepatide in type 2 diabetes, n = 7769) [8] did not report EKA, suggesting that if a risk exists, it is very rare and typically requires additional modifiers such as…”
Howie, J. O., Dziano, J. K., Ariyaratnam, J., Emami, M., Evans, S., Middeldorp, M. E., Puvrez, A., Kenny, G., Sanders, P., & Elliott, A. D. (2026) · Heart Rhythm O2 · doi:10.1016/j.hroo.2026.07.006
Hamzeh, B. F., Orear, C. R., Mardourian, M., Keeter, C., Egan, K. G., Winocour, J., Kokosis, G., Mathes, D. W., & Kaoutzanis, C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135042
Faut-il faire maigrir les patients ayant une insuffisance respiratoire chronique et une obésité ?
Borel, A., Suzeau, P., & Borel, J. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.06.004
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
